Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the efficacy of the association of Lenalidomide
(Revlimid) and R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, vincristine and Prednisone)
in a population of patients with follicular lymphoma as measured by the response rate at the
end of treatment.